SLN Stock — Silence Therapeutics Plc American Depository Share: Cash, EV, Pipeline

Share price

$12.20

Market cap

$571.0M

Cash

$236.1M

Enterprise value

$334.9M

Balance sheet

Cash	$236.1M
Debt	$0.0M
Net cash	$236.1M
Enterprise value	$334.9M
Basic shares	141.7M shares
Fully diluted shares	149.4M shares
Fully diluted market cap	$1,823.0M
Cash per share	$1.67

Cash figures as of 2026-08-13. Database snapshot: 2026-09-21.

Price history

Loading SLN daily closes…

Loading price history…

Pipeline assets

Divesiran

Phase 2 · Active Modality: siRNA

Aliases SLN124

Target TMPRSS6

Indications

polycythemia vera (PV) (Phase 2)

Catalysts

— Q3 2026

Status note Phase 2 SANRECO dosing completed; first-in-class siRNA silencing TMPRSS6.

SLN548

Preclinical · Active Modality: siRNA

Target CFB (complement factor B)

Indications

complement-mediated renal diseases (Preclinical)

Status note Phase 1-ready; seeking a third-party partner to initiate clinical development.

Zerlasiran

Phase 2 · Active Modality: siRNA

Aliases SLN360

Target LPA

Indications

cardiovascular disease (elevated lipoprotein(a)) (Phase 2)

Status note Described as Phase 3-ready; no Phase 3 initiated per filing, so stage is kept at Phase 2.

SLN312

Phase 1 · Active Modality: siRNA

Aliases AZD1705

Target ANGPTL3

Partnerships AstraZeneca (collaboration; AZ will not pursue beyond Phase 1, Silence regains full global rights)

Indications

dyslipidemia (Phase 1)

Status note Phase 1 results presented May 2026; Silence evaluating plans for further clinical development; no discontinuation disclosed.

SLN365

Preclinical · Active Modality: siRNA

Target GPR146

Indications

hypercholesterolemia (Preclinical)

Catalysts

— 2027

Status note Preclinical; well positioned for a potential IND filing in 2027.

SLN098

Preclinical · Active Modality: siRNA

Target INHBE

Indications

obesity (Preclinical)

Status note Preclinical.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	SLN124
Lead indication	Polycythemia Vera
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05499013	Phase 2	Active, not recruiting	Sponsor	SLN	—	Polycythemia Vera	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Silence Therapeutics plc on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	830,784	-35,000	0.30%	2026-08-14
ADAR1 Capital Management	338,373	+166,216	0.17%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

SLN — Silence Therapeutics Plc American Depository Share

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials

Institutional holders